<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>F.D.A. DOES NOT APPROVE AKZO NOBEL UNIT'S ANTIDEPRESSANT</title>
    <meta content="CN005312" name="slug"/>
    <meta content="26" name="publication_day_of_month"/>
    <meta content="6" name="publication_month"/>
    <meta content="2004" name="publication_year"/>
    <meta content="Saturday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="4" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="1" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1592289"/>
      <doc.copyright holder="The New York Times" year="2004"/>
      <series series.name="COMPANY NEWS"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Mental Health and Disorders</classifier>
        <classifier class="indexing_service" type="descriptor">Gepirone Er (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Variza (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Depression (Mental)</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <org class="indexing_service">Food and Drug Administration</org>
        <org class="indexing_service">Organon Inc</org>
        <org class="indexing_service">Akzo Nobel Nv</org>
        <person class="indexing_service">Crouch, Gregory</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Mental Health and Behavior</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Depression</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health/Diseases, Conditions, and Health Topics/Mental Health and Disorders</classifier>
        <classifier class="online_producer" type="general_descriptor">Depression (Mental)</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Mental Health and Disorders</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20040626T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9C04E3D61638F935A15755C0A9629C8B63" item-length="112" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>F.D.A. DOES NOT APPROVE AKZO NOBEL UNIT'S ANTIDEPRESSANT</hl1>
      </hedline>
      <byline class="print_byline">By Gregory Crouch (NYT)</byline>
      <byline class="normalized_byline">Crouch, Gregory</byline>
      <abstract>
        <p>Akzo Nobel says its Organon USA division failed to win FDA approval for its antidepressant Gepirone, also known as Variza (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>The pharmaceutical and chemicals company Akzo Nobel said yesterday that its Organon USA division failed to win approval from the Food and Drug Administration for its antidepressant Gepirone, also known as Variza. Akzo Nobel hoped to generate hundreds of millions of dollars a year selling Gepirone. The announcement was another blow to Akzo's struggling pharmaceutical division, which has lost sales since the release in the United States of generic competitors to its best-selling antidepressant Remeron.</p>
        <p>Gregory Crouch (NYT)</p>
      </block>
      <block class="full_text">
        <p>The pharmaceutical and chemicals company Akzo Nobel said yesterday that its Organon USA division failed to win approval from the Food and Drug Administration for its antidepressant Gepirone, also known as Variza. Akzo Nobel hoped to generate hundreds of millions of dollars a year selling Gepirone. The announcement was another blow to Akzo's struggling pharmaceutical division, which has lost sales since the release in the United States of generic competitors to its best-selling antidepressant Remeron.</p>
        <p>Gregory Crouch (NYT)</p>
        <p>COMPANY NEWS</p>
      </block>
    </body.content>
  </body>
</nitf>
